Preview: India's Cipla faces U.S. headwinds in Q1, likely overshadowing resilient domestic business

Cipla

23/07/2026 06:42

** Shares of India's Cipla CIPL.NS down 0.13% to 1414.80 rupees ahead of first quarter results
** On an average, analysts expect drugmaker to post a 36.6% year-on-year drop in June quarter profit to 8.23 billion rupees ($85.27 million) -- data compiled by LSEG
** Co expected to post 1.7% y/y rise in first quarter revenue to 70.73 billion rupees -- LSEG data
** Antique Stock Broking expects Cipla's domestic formulations business to remain resilient, but says weaker US sales due to lower gRevlimid sales and Lanreotide supply issues will weigh on margins
** PhillipCapital expects Cipla's earnings to decline as lower gRevlimid sales, regulatory restrictions on Lanreotide and a lack of meaningful new launches offset healthy domestic formulations growth and currency tailwinds
** CIPL rated "buy" on average by 37 analysts, median PT at 1500 rupees-LSEG compiled data
** YTD stock down 6.55%


($1 = 96.5200 Indian rupees)

 (Reporting by Surbhi Misra in Bengaluru)
 ((Surbhi.Misra@thomsonreuters.com |  X: https://twitter.com/SurbhiMisra_  |;))